| Date Filed | Type | Description |
| 10/05/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/21/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 08/21/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/18/2023 |
4
| Sarnoff David (Director) has filed a Form 4 on Hoth Therapeutics, Inc.|
Txns:
| Granted 7,500 options
@ $2.59, valued at
$19.4k
|
|
| 07/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/18/2023 |
4
| Knie Robb (CEO and President) has filed a Form 4 on Hoth Therapeutics, Inc.|
Txns:
| Granted 40,000 options
@ $2.59, valued at
$103.6k
|
|
| 07/18/2023 |
4
| Pavell Jeff (Director) has filed a Form 4 on Hoth Therapeutics, Inc.|
Txns:
| Granted 7,500 options
@ $2.59, valued at
$19.4k
|
|
| 07/18/2023 |
4
| Linsley Wayne (Director) has filed a Form 4 on Hoth Therapeutics, Inc.|
Txns:
| Granted 7,500 options
@ $2.59, valued at
$19.4k
|
|
| 06/06/2023 |
8-K
| Other Events Interactive Data |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/28/2023 |
8-K
| Other Events Interactive Data |
| 02/14/2023 |
SC 13G
| ARMISTICE CAPITAL, LLC reports a 10% stake in Hoth Therapeutics, Inc. |
| 02/08/2023 |
SC 13G/A
| INTRACOASTAL CAPITAL, LLC reports a 4.2% stake in Hoth Therapeutics, Inc. |
| 01/26/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 01/26/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/13/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 01/04/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 12/30/2022 |
8-K
| Quarterly results |
| 12/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/13/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 12/13/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 11/14/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/10/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 11/03/2022 |
8-K
| Quarterly results |
| 10/24/2022 |
8-K
| Quarterly results |
| 09/20/2022 |
4
| Knie Robb (CEO and President) has filed a Form 4 on Hoth Therapeutics, Inc.|
Txns:
| Bought 10,000 shares
@ $0.39, valued at
$3.9k
|
|
| 09/19/2022 |
4
| Knie Robb (CEO and President) has filed a Form 4 on Hoth Therapeutics, Inc.|
Txns:
| Bought 10,000 shares
@ $0.4, valued at
$4k
|
|
| 08/22/2022 |
8-K
| Quarterly results |
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/18/2022 |
8-K
| Quarterly results |
|